Search - tctmd.com

Displaying 21 - 40 of 351

Sort: Relevancy | Date

News Daily News

Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says

Caitlin E. Cox

April 17, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Daily News

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

Caitlin E. Cox

February 26, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

European Medicines Agency Investigating GLP-1 Drugs and Eye Disease

L.A. McKeown

January 21, 2025

News Features

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Michael O'Riordan

January 17, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

News Daily News

Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis

Todd Neale

November 28, 2024

News Daily News

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

Todd Neale

November 27, 2024

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Conference News AHA 2024

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Michael O'Riordan

November 17, 2024

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News AHA 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Yael L. Maxwell

November 16, 2024

Advertisement

Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

January 2025 Dispatch for the CV Team

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

European Medicines Agency Investigating GLP-1 Drugs and Eye Disease

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Top General Cardiology and Prevention News of 2024

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

November 2024 Dispatch for the CV Team

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content